DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/c34d4b/clinical_trial_end) has announced the addition of the "Clinical Trial Endpoints in Oncology - Inclusion of Surrogate Endpoints and Shorter Endpoints Will Ensure Faster Clinical Trials in Oncology" report to their offering.
Clinical Trial Endpoints in Oncology - Inclusion of Surrogate Endpoints and Shorter Endpoints will Ensure Faster Clinical Trials in Oncology provides in-depth analysis of the endpoints and application of endpoints in oncological clinical trials. The report analyzes the four major therapeutic area involved, which include colorectal cancer, prostate cancer, head and neck cancer and ovarian cancer. The report includes analysis of endpoints of major oncological market products and profiles. In addition to marketed products, the Phase III and Phase II clinical trials are also analyzed in terms of percentage cases. Analysis of terminated trials is also included in the report. Furthermore, the report provides competitive benchmarking for the leading companies and profiling of major companies in the oncology market.
It is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.
Survival - Primary Endpoint in Majority of the Market Products
The primary endpoint for the approval of drugs in the oncology markets, which included colorectal, ovarian, head, neck and prostate cancer, was survival. The other endpoints in these markets were response rate (complete, partial, objective, overall response rate and so on). The major marketed drugs approved after 1990 in the colorectal cancer market were Camptosar (irinotecan), Xeloda (capecitabine), Avastin (Bevacizumab), Erbitux (cetuximab), Vectibix (panitumumab) and Eloxatin (oxaliplatin). The primary endpoint in all these drugs was survival, followed by median time to tumor progression, tumor response rate, progression-free survival, overall response rate and duration of response. In the prostate cancer market, the major marketed products were Taxotere (docetaxel), Casodex (Bicalutamide), Zoladex (Goserelin), Provenge (sipuleucel-T), Eligard (leuprolide acetate), Prostap (leuprolide acetate), Firmagon (degarelix), Vantas (Histrelin), Novantrone (Mitoxantrone hydrochloride), Trelstar (triptorelin). The primary and secondary endpoints in these included the median survival rate, prostate specific antigen (PSA) response, overall tumor response rate, disease-free survival, objective response, serum testosterone level and time to disease progression.
The major marketed drugs after 1990 approved for head and neck cancer were Erbitux (cetuximab), Taxotere (docetaxel), Oncorine (H101, Modified Adenovirus) and Gendicine (Recombinant Human Ad-P53). The primary and secondary endpoints in these included median and overall survival rate, progression-free survival and complete response rate. Similarly, the major marketed drugs after 1990 approved for ovarian cancer were Altretamine (Hexalen), Gemcitabine (Gemzar), Hycamtin (Topotecan hydrochloride) and Yondelis (trabectedin). The primary and secondary endpoints of these drugs included overall and complete response rate, progression-free survival, time to response and overall survival.
Scope:
- Data and analysis on the marketed products and analysis of endpoints used for the approval of the product.
- Analysis of the four major markets, which includes the colorectal cancer, prostate cancer, head and neck cancer and ovarian cancer therapeutics markets.
- Analysis of the Phase III and Phase II clinical trials in terms of percentage cases. Analysis of terminated trials is also included in this chapter. Only industry sponsored studies are included in the report.
- Trend Analysis analyzes prevailing and upcoming trends and their effects on the market.
- Company Profiling talks in detail about the companies which are strong in the market.
Reasons to Buy:
- Build an effective R&D strategy by identifying the current state of endpoint achieved by the marketed products
- Identify the disease unmet needs for the four major cancers and align your pipeline product portfolio to tap the market potential.
- Improve our future market position by aligning your R&D pipeline to the areas with maximum success potential
- Improve your R&D efficiency by reducing research expenditure on unsuccessful endpoints
- Develop key strategic initiatives by understanding the key focus of leading companies with strong product pipeline.
Key Topics Covered:
1 Table of Contents
2 Clinical Trials Endpoints In Oncology - Introduction
3 Clinical Trials Endpoints In Oncology - Market Overview
4 Clinical Trials Endpoints in Oncology - Therapeutic Analysis
5 Clinical Trials Endpoints In Oncology - New Trends and Technologies
6 Clinical Trials Endpoints In Oncology - Company Profiling
7 Clinical Trials Endpoints In Oncology - Appendix
Companies Mentioned:
- F. Hoffmann La Roche
- Bristol-Myers Squibb
- Sanofi-Aventis
- Merck KGaA
- Pfizer Inc.
- AstraZeneca
- Takeda Pharmaceuticals
- GlaxoSmithKline plc.
For more information visit http://www.researchandmarkets.com/research/c34d4b/clinical_trial_end